DIAGNOSTIC SIGNIFICANCE OF OBESITY PHENOTYPE`S METABOLIC CRITERIA IN FEMALES AND THEIR CONNECTION WITH ACCOMPANYING DISEASES AND STATES

DOI: https://doi.org/10.29296/25877305-2020-11-14
Download full text PDF
Issue: 
11
Year: 
2020

M. Lyasnikova, Candidate of Medical Sciences; Professor N. Belyakova, MD; N. Milaya; I.
Tsvetkova, Candidate of Medical Sciences; L. Slezkina, Candidate of Medical Sciences; A. Lareva, Candidate
of Medical Sciences Tver State Medical University of Healthcare Ministry of Russian Federation

The aim of present investigation was to study the role of different diagnostic criteria of phenotypes and their correlation with diseases and states associated with alimentary-constitutional obesity in females. Methods. There were examined 273 females with over weight and alimentary-constitutional obesity. Examination included anthropometry, measurement of blood pressure (BP), laboratory tests. All patients were separated on 4 groups depending on age and phenotype:1-st patients with normal sensitivity to insulin and without other characteristics of MS (30%); 2-nd – females with the resistance to insulin and without MS characteristics (15%); 3-d included patients with the insulin resistance and MS characteristics (37,8%); 4-th group – females with MS and normal sensitivity to insulin (17,2%). Results. Cardiovascular risks and phenotype of obesity are mostly determined by sensitivity to insulin and MS characteristics (triglycerides level, Cholesterol of high density and WC). Insuline resistance, already presented at young age, in 50% is accompanied by fat hepatitis, elevation of cholesterol total, Cholesterol of lipoproteines, leptine blood level and is a risk factor of development of MS on oldery. Metabolic syndrome, presented without insulin resistance, should be attributed to non-healthy obesity, because it increases cardio-vascular risk and in these patients fat hepatitis and hormonal and metabolic disbalances are confirmed more often.
Keywords: 
endocrinology
obesity
metabolic phenotype
insulin resistance
metabolic syndrome

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Krysanova V.S., Zhuravleva M.V., Serebrova S.Ju. Sotsial'naja i ekonomicheskaja znachimost' izbytochnoj massy tela i ozhirenija v Rossijskoj Federatsii. Osnovnye podhody k lecheniju ozhirenija. RMZh. 2015; 23 (26): 1534–7 [Krysanova V.S., Zhuravleva M.V., Serebrova S.Y. Sotsial’naya i ekonomicheskaya znachimost’ izbytochnoi massy tela i ozhireniya v Rossiiskoi Federatsii. Osnovnye podkhody k lecheniyu ozhireniya. RMJ. 2015; 23 (26): 1534–7 (in Russ.)].
  2. Starodubova A.V., Starodubov V.I. Tendentsii, vozrastnye i regional'nye osobennosti zabolevaemosti ozhireniem naselenija Rossijskoj Federatsii v 1992–2012 gg. Profilakticheskaja meditsina. 2017; 6: 32–40 [Starodubova A.V., Starodubov V.I. Obesity trends and age-related and regional features in the Russian Federation in 1992–2012. Profilakticheskaya meditsina. 2017; 6: 32–40 (in Russ.)]. DOI: 10.17116/profmed201720632-40
  3. Verbovoj A.F., Sharonova L.A., Pashentseva A.V. i dr. Insulinorezistentnost' i zabolevanija vnutrennih organov. Vrach. 2017; 9: 17–22 [Verbovoy A., Sharonova L., Pashentseva A. et al. Insulin resistance and diseases of the internal organs. Vrach. 2017; 9: 17–22 (in Russ.)].
  4. Collins K.H., Herzog W., MacDonald G.Z. et al. Obesity, Metabolic Syndrome, and Musculoskeletal Disease: Common Inflammatory Pathways Suggest a Central Role for Loss of Muscle Integrity. Front Physiol. 2018; 9: 112. DOI:10.3389/fphys.2018.00112
  5. Meigs J.B., Wilson P.W., Fox C.S. et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006; 91 (8): 2906–12. DOI: 10.1210/jc.2006-0594
  6. Thompson J., Regnault T. In Utero Origins of Adult Insulin Resistance and Vascular Dysfunction. Semin Reprod Med. 2011; 29 (03): 211–24. DOI: 10.1055/s-0031-1275522
  7. Samorodskaja I.V. Ozhirenie: nadezhnost' kriteriev otsenki, sootnoshenie vreda i pol'zy. Vrach. 2014; 4: 5–8 [Samorodskaya I. Obesity: assessment criteria reability, hazard-benefit ratio. Vrach. 2014; 4: 7–8 (in Russ.)].
  8. Stefan N., Haring H.U. Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med. 2013; 19 (4): 394–5. DOI: 10.1038/nm.3116
  9. Ostrovskaja E.V., Romantsova T.I., Gerasimov A.N. i dr. Rasprostranennost' metabolicheski zdorovogo ozhirenija po dannym vyborki Moskovskogo regiona. Ozhirenie i metabolizm. 2017; 14 (4): 51–6 [Ostrovskaya E.V., Romantsova T.I., Gerasimov A.N. et al. The prevalence of metabolically healthy obesity according to the sample of the Moscow region. Obesity and metabolism. 2017; 14 (4): 51–6 (in Russ.)]. DOI: 10.14341/OMET2017451-56
  10. Aguilar-Salinas C.A., Garcia E.G., Robles L. et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab. 2008; 93 (10): 4075–9. DOI: 10.1210/jc.2007-2724
  11. Agafonova O.V., Gritsenko T.A., Bogdanova Ju.V. i dr. Poliklinicheskaja terapija: Uchebnik. Pod red. D.I. Davydkina, Ju.V. Schukina. 2-e izd., pererab. i dop. M.: GEOTAR-Media, 2020; 840 s. [Agafonova O.V., Gritsenko T.A., Bogdanova Yu.V. et al. Poliklinicheskaya terapiya: Uchebnik. Pod red. D.I. Davydkina, Yu.V. Shchukina. 2-e izd., pererab. i dop. M.: GEOTAR-Media, 2020; 840 s. (in Russ.)]. DOI: 10.33029/9704-5545-6-PLT-2020-1-840
  12. Berezina A., Belyaeva O., Berkovich O. et al. Prevalence, Risk Factors, and GeneticTraits in Metabolically Healthy and Unhealthy Obese Individuals. BioMed Res Int. 2015; 2015: 1–9. DOI: 10.1155/2015/548734
  13. Diagnostika, lechenie, profilaktika ozhirenija i assotsiirovannyh s nim zabolevanij. Natsional'nye klinicheskie rekomendatsii. SPb, 2017 [Diagnostika, lechenie, profilaktika ozhireniya i assotsiirovannykh s nim zabolevanii. Natsional’nye klinicheskie rekomendatsii. SPb, 2017 (in Russ)] Rezhim dostupa / Available from: https://mirvracha.ru/article/klinicheskie_rekomendatsii_po_diagnostike_i_lecheniyu_ozhireniya
  14. Wildman R.P., Muntner P., Reynolds K. et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008; 168 (15): 1617–24. DOI: 10.1097/01.ogx.0000338100.83483.58
  15. Suplotova L.A., Smetanina S.A., Plotnikov N.V. Kliniko-metabolicheskie i molekuljarno-geneticheskie assotsiatsii u zhenschin reproduktivnogo vozrasta pri insulinorezistentnosti, ozhirenii i metabolicheskom sindrome. Meditsinskaja nauka i obrazovanie Urala. 2013; 2 (74): 84–7 [Suplotova L.A., Smetanina S.A., Plotnikov N.V. et al. Associations of clinical, metabolic and molecular genetic markers of insulin resistance for womens of reproductive age with obesity and metabolic syndrome. Meditsinskaya nauka i obrazovanie Urala. 2013; 2 (74): 84–7 (in Russ.)].
  16. Hamedova M.Sh., Serebrjakova V.N., Trubacheva I.A. i dr. Rasprostranennost' otdel'nyh komponentov metabolicheskogo sindroma sredi pedagogov. Sibirskij meditsinskij zhurnal. 2013; 3 (28): 77–81 [Khamedova M.Sh., Serebryakova V.N., Trubacheva I.A. et al. Prevalence of separate components of metabolic syndrome among secondary school teachers. Sibirskii meditsinskii zhurnal. 2013; 3 (28): 77–81 (in Russ.)].
  17. Smirnova E.N., Shul'kina S.G. Soderzhanie leptina, rastvorimyh retseptorov leptina i indeksa svobodnogo leptina u bol'nyh s metabolicheskim sindromom. Ozhirenie i metabolizm. 2017; 14 (1): 30–4 [Smirnova E.N., Shulkina S.G. Leptin, soluble leptin receptor and the free leptin index in patients with metabolic syndrome. Obesity and metabolism. 2017; 14 (1): 30–4 (in Russ.)]. doi: 10.14341/0MET2017130-34. URL: https://cyberleninka.ru/article/n/soderzhanie-leptina-rastvorimyh-retseptorov-leptina-i-indeksa-svobodnogo-leptina-u-bolnyh-s-metabolicheskim-sindromom
  18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285 (19): 2486–97. DOI: 10.1001/jama.285.19.2486